The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.
Age is 18 years old or above.
Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA.
Randomized within 24h after the onset.
The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination;
Intracranial hemorrhage confirmed by CT or MRI.
mRS score>2 for patients <80 years, or mRS score>1 for those ≥80 years before onset.
Pregnant or lactating women.
Allergic to contrast agents.